Hermes Medical Solutions (HMS), a global market leader in molecular imaging and dosimetry software solutions, is now in close collaboration with Isotopia to raise awareness and co-promote the benefits of dosimetry, radiopharmaceutical therapy (RPT) and personalized medicine.
As
recently presented in a plenary presentation at the 2021 American Society of
Clinical Oncology (ASCO) held in June, radiopharmaceutical therapies clearly demonstrate
enormous potential in the battle against cancer.
The
first results of the international phase III VISION trial, establish that
[177]Lu-PSMA-617 can be safely added to the standard of care (SOC) treatment
and improve radiographic progression-free survival (rPFS) as well as prolonging
the overall survival compared with SOC alone in men with advanced-stage
PSMA-positive metastatic castration-resistant prostate cancer (mCRPC),
supporting its adoption as a standard of care.
To
read more please visit:
Source: CISION